Shots:

• Austedo has received its second approval from NMPA (prior CFDA) following the US FDA’s approval to treat tardive dyskinesia and chorea associated with Huntington’s disease in adults
• The approval was completed within four months post granting of Priority Review by the NMPA and has also placed Austedo on the List of Overseas New Drugs Urgently Needed in Clinical Settings (the First Batch)
• Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor and will be commercialized by Teva in China following the recent launch of Treanda

Click here to read full press release/ article | Ref: Teva | Image: Behnace